Search Results - "HOCHMAN, J. S."

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost‐effectiveness analysis by LALA, A., BERGER, J. S., SHARMA, G., HOCHMAN, J. S., SCOTT BRAITHWAITE, R., LADAPO, J. A.

“…Background:  The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary…”
Get full text

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib by Farkouh, M E, Greenberg, J D, Jeger, R V, Ramanathan, K, Verheugt, F W A, Chesebro, J H, Kirshner, H, Hochman, J S, Lay, C L, Ruland, S, Mellein, B, Matchaba, P T, Fuster, V, Abramson, S B

“…Background: Evidence suggests that both selective cyclooxygenase (COX)-2 inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) increase…”
Get full text

Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry by Dzavik, V., Sleeper, L.A., Cocke, T.P., Moscucci, M., Saucedo, J., Hosat, S., Jiang, X., Slater, J., LeJemtel, T., Hochman, J.S.

“…Aims The SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) Trial showed no benefit of early revascularization in patients…”
Get full text

Mechanical circulatory support in cardiogenic shock by Werdan, Karl, Gielen, Stephan, Ebelt, Henning, Hochman, Judith S

“…Despite advances in coronary revascularization and widespread use of primary percutaneous interventions, cardiogenic shock complicating an acute ST-elevation…”
Get full text

One-Year Survival Following Early Revascularization for Cardiogenic Shock by Hochman, Judith S, Sleeper, Lynn A, White, Harvey D, Dzavik, Vladimir, Wong, S. Chiu, Menon, Venu, Webb, John G, Steingart, Richard, Picard, Michael H, Menegus, Mark A, Boland, Jean, Sanborn, Timothy, Buller, Christopher E, Modur, Sharada, Forman, Robert, Desvigne-Nickens, Patrice, Jacobs, Alice K, Slater, James N, LeJemtel, Thierry H, for the SHOCK Investigators

“…CONTEXT Cardiogenic shock (CS) is the leading cause of death for patients hospitalized with acute myocardial infarction (AMI). OBJECTIVE To assess the effect…”
Get full text

American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents by Bashore, T M, Bates, E R, Berger, P B, Clark, D A, Cusma, J T, Dehmer, G J, Kern, M J, Laskey, W K, O'Laughlin, M P, Oesterle, S, Popma, J J, O'Rourke, R A, Abrams, J, Brodie, B R, Douglas, P S, Gregoratos, G, Hlatky, M A, Hochman, J S, Kaul, S, Tracy, C M, Waters, D D, Winters, Jr, W L

Get full text

Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry by Menon, V, Slater, J N, White, H D, Sleeper, L A, Cocke, T, Hochman, J S

“…Cardiogenic shock is usually characterized by inadequate cardiac output and sustained hypotension. However, following a large myocardial infarction, peripheral…”
Get more information

Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage by HOCHMAN, J. S, CHOO, H

“…Very early reperfusion after coronary occlusion can reduce infarct size and preserve left ventricular function. Whether later reperfusion is of benefit is…”
Get full text

Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation by HOLMES, D. R, BERGER, P. B, HOCHMAN, J. S, GRANGER, C. B, THOMPSON, T. D, CALIFF, R. M, VAHANIAN, A, BATES, E. R, TOPOL, E. J

“…Cardiogenic shock is usually considered a sequela of ST-segment elevation myocardial infarction. There are limited prospective data on the incidence and…”
Get full text

Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm by HOCHMAN, Judith S

Get full text

Lack of progress in cardiogenic shock: lessons from the GUSTO trials by Menon, V, Hochman, J.S, Stebbins, A, Pfisterer, M, Col, J, Anderson, R.D, Hasdai, D, Holmes, D.R, Bates, E.R, Topol, E.J, Califf, R.M, Ohman, E.M

“…Aims We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results…”
Get full text

First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial by ALEXANDER, J. H., YANG, H., BECKER, R. C., KODAMA, K., GOODMAN, S., DYKE, C. K., KLEIMAN, N. S., HOCHMAN, J. S., BERGER, P. B., COHEN, E. A., LINCOFF, A. M., BURTON, J. R., BOVILL, E. G., KAWAI, C., ARMSTRONG, P. W., HARRINGTON, R. A.

“…Background: Unfractionated heparin is widely used in patients with non‐ST‐elevation acute coronary syndromes but has important limitations. Anticoagulants with…”
Get full text

A new regimen for heparin use in acute coronary syndromes by Hochman, Judith S., Wali, Andreas U., Gavrila, Dan, Sim, Min J., Malhotra, Sanjay, Palazzo, Angela M., De La Fuente, Beatriz

“…Background Recent trials have demonstrated an association between high activated partial thromboplastin time (aPTT) and bleeding, intracranial hemorrhage,…”
Get full text

Fatal Cardiac rupture among Patients treated with thrombolytic agents and adjunctive Thrombin antagonists : Observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study by BECKER, R. C, HOCHMAN, J. S, CANNON, C. P, SPENCER, F. A, BALL, S. P, RIZZO, M. J, ANTMAN, E. M

“…The purpose of this study was to determine the incidence and demographic characteristics of patients experiencing cardiac rupture after thrombolytic and…”
Get full text

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot by Alexander, J. H., Dyke, C. K., Yang, H., Becker, R. C., Hasselblad, V., Zillman, L. A., Kleiman, N. S., Hochman, J. S., Berger, P. B., Cohen, E. A., Lincoff, A. M., Saint‐Jacques, H., Chetcuti, S., Burton, J. R., Buergler, J. M., Spence, F. P., Shimoto, Y., Robertson, T. L., Kunitada, S., Bovill, E. G., Armstrong, P. W., Harrington, R. A.

“…Background: Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI)…”
Get full text

ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) by Braunwald, Eugene, Antman, Elliott M, Beasley, John W, Califf, Robert M, Cheitlin, Melvin D, Hochman, Judith S, Jones, Robert H, Kereiakes, Dean, Kupersmith, Joel, Levin, Thomas N, Pepine, Carl J, Schaeffer, John W, Smith, Earl E, Steward, David E, Theroux, Pierre, Gibbons, Raymond J, Alpert, Joseph S, Eagle, Kim A, Faxon, David P, Fuster, Valentin, Gardner, Timothy J, Gregoratos, Gabriel, Russell, Richard O, Smith, Sidney C

Get full text

American College of Cardiology/American heart association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease by O'Rourke, R A, Brundage, B H, Froelicher, V F, Greenland, P, Grundy, S M, Hachamovitch, R, Pohost, G M, Shaw, L J, Weintraub, W S, Winters, Jr, W L, Forrester, J S, Douglas, P S, Faxon, D P, Fisher, J D, Gregoratos, G, Hochman, J S, Hutter, Jr, A M, Kaul, S, Wolk, M J

Get full text

Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I by Greenberg, H. M., Dwyer, E. M., Hochman, J. S., Steinberg, J. S., Echt, D. S., Peters, R. W.

“…OBJECTIVE--To determine whether an interaction between encainide or flecainide and intercurrent ischaemia could account for the observed increase in cardiac…”
Get full text

Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition : Insights from the platelet glycoprotein IIb/IIIa in unstable angina : Receptor suppression using integrilin therapy (PURSUIT) trial by LINCOFF, A. M, HARRINGTON, R. A, BERDAN, L. G, KITT, M. M, SIMOONS, M. L, TOPOL, E. J, CALIFF, R. M, HOCHMAN, J. S, GUERCI, A. D, OHMAN, E. M, PEPINE, C. J, KOPECKY, S. L, KLEIMAN, N. S, PACCHIANA, C. M

“…A multinational, randomized, placebo-controlled trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,…”
Get full text

Has the time come to seek and open all occluded infarct-related arteries after myocardial infarction? by Hochman, J S

Get full text